TITLE

The Solubility Ceiling: A Rationale for Continuous Infusion Amphotericin B Therapy?

AUTHOR(S)
Lewis, Russell E.; Wiederhold, Nathan P.
PUB. DATE
September 2003
SOURCE
Clinical Infectious Diseases;9/15/2003, Vol. 37 Issue 6, p871
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor in the September 15, 2003 issue of 'Clinical Infectious Diseases,' regarding the article 'Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study,' by A. Imhof et al.
ACCESSION #
10868963

 

Related Articles

  • Mycograb for the Treatment of Invasive Candidiasis. Herbrecht, Raoul; Fohrer, Cécile; Nivoix, Yasmine // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p1083 

    A letter to the editor is presented in response to the paper by Pachl and colleagues which provide the results of a double-blind study comparing Mycograb with a placebo plus a lipid-assocated formulation of amphotericin B for the treatment of invasie candidiasis.

  • Reply to Herbrecht et al. Matthews, Ruth // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p1083 

    A letter to the editor is presented in response to comments made on the author's article by Herbrecht and colleages regarding the double-blind trial comparing combination therapy with Mycograb plus lipid-associated amphotericin B with amphotericin B monotherapy.

  • Effects of antimicrobial drug shortages. Ferrández, Olivia; Antonio, Javier Mateu-de; Grau, Santiago // American Journal of Health-System Pharmacy;7/15/2005, Vol. 62 Issue 14, p1444 

    Presents a letter to the editor on the adverse effects of shortage in the supply of amphotericin B, an antimicrobial drug.

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Ullmann, Andrew J.; Heussel, Claus Peter; Cornely, Oliver A. // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A letter to the editor is presented in response to an article about a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue.

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Apisarnthanarak, Anucha; Little, J. Russell; Tebas, Pablo // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A letter to the editor is presented in response to an article about a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue.

  • Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. Walsh, Thomas J.; Pappas, Peter G.; Winston, Drew J. // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1745 

    A response by Thomas J. Walsh and colleagues to a letter to the editor about their article on a trial of voriconazole, as compared with liposomal amphotericin B, for patients with neutropenia and persistent fever in the January 12, 2002 issue is presented.

  • Voriconazole versus Amphotericin B for Invasive Aspergillosis. Herbrecht, Raoul; Patterson, Thomas F.; Bennett, John E. // New England Journal of Medicine;12/19/2002, Vol. 347 Issue 25, p2080 

    A response by R. Herbrecht, D.W. Denning, and T.F. Patterson to several letters to the editor about their article "Voriconazole Versus Amphotericin B for Primary Therapy of Invasive Aspergillosis," in the August 8, 2002 issue.

  • Liposomal Amphotericin B Trial Marred by Conclusions. WoIf, Joshua; Buttery, Jim; Daley, Andrew J.; Hanieh, Sarah; Shann, Frank; Starr, Mike; Curtis, Nigel // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, p667 

    A letter to the editor is presented in response to the article "Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing," by O. A. Cornely and colleagues in the 2007 issue.

  • Reply to Wolf et al. Cornely, Oliver A.; Maetens, Johan; Herbrecht, Raoul // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, p668 

    A reply by O. A. Cornely and colleagues to a letter to the editor about their article "Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing" in the 2007 issue is presented.

  • Lipid Formulations of Amphotericin B and Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis. Soonawala, Darius; Landman, Gijs W.; van't Wout, J. W. // Clinical Infectious Diseases;6/1/2010, Vol. 50 Issue 11, p1544 

    A letter to the editor is presented in response to the article about lipid formulations of amphotericin B by Sun and colleagues in the 2010 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics